392 related articles for article (PubMed ID: 33348563)
1. Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.
Yarla NS; Madka V; Pathuri G; Rao CV
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348563
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: ready for routine use?
Arber N; Levin B
Recent Results Cancer Res; 2005; 166():213-30. PubMed ID: 15648192
[TBL] [Abstract][Full Text] [Related]
3. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase as a target for colorectal cancer chemoprevention.
Moreira L; Castells A
Curr Drug Targets; 2011 Dec; 12(13):1888-94. PubMed ID: 21158711
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of colorectal cancer: Past, present, and future.
Umezawa S; Higurashi T; Komiya Y; Arimoto J; Horita N; Kaneko T; Iwasaki M; Nakagama H; Nakajima A
Cancer Sci; 2019 Oct; 110(10):3018-3026. PubMed ID: 31361372
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of colorectal cancer: ready for routine use?
Arber N; Levin B
Curr Top Med Chem; 2005; 5(5):517-25. PubMed ID: 15974946
[TBL] [Abstract][Full Text] [Related]
7. Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation.
Miguchi M; Hinoi T; Shimomura M; Adachi T; Saito Y; Niitsu H; Kochi M; Sada H; Sotomaru Y; Ikenoue T; Shigeyasu K; Tanakaya K; Kitadai Y; Sentani K; Oue N; Yasui W; Ohdan H
PLoS One; 2016; 11(11):e0166422. PubMed ID: 27835699
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
9. Colon cancer: preventive agents and the present status of chemoprevention.
Half E; Arber N
Expert Opin Pharmacother; 2009 Feb; 10(2):211-9. PubMed ID: 19236194
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of colorectal cancer: feasibility in everyday practice?
Herszényi L; Farinati F; Miheller P; Tulassay Z
Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 as target for chemopreventive interventions: new approaches.
Dvory-Sobol H; Arber N
Cancer Biomark; 2007; 3(3):153-61. PubMed ID: 17611306
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer: from prevention to personalized medicine.
Binefa G; Rodríguez-Moranta F; Teule A; Medina-Hayas M
World J Gastroenterol; 2014 Jun; 20(22):6786-808. PubMed ID: 24944469
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy.
Benelli R; Venè R; Ferrari N
Transl Res; 2018 Jun; 196():42-61. PubMed ID: 29421522
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of colorectal cancer - a new target needed?
Spychalski M; Dziki L; Dziki A
Colorectal Dis; 2007 Jun; 9(5):397-401. PubMed ID: 17504335
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection.
Castellone MD; Teramoto H; Gutkind JS
Cancer Res; 2006 Dec; 66(23):11085-8. PubMed ID: 17145847
[TBL] [Abstract][Full Text] [Related]
17. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
19. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Reddy BS
Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
[Next] [New Search]
